The startup develops automated microfluidic 3D cellular assays that enable the testing of up to 800 conditions on 1,000 microtumors simultaneously, significantly reducing the required patient sample size. This technology accelerates drug discovery and enhances the predictability of patient-specific responses to cancer therapies, addressing the inefficiencies in traditional biopsy testing methods.
Funding
$11.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of testing cancer therapies rely on large patient sample sizes and are often slow and labor-intensive, hindering drug discovery and personalized medicine efforts. Existing biopsy testing methods can be inefficient and may not accurately predict patient-specific responses to treatment.
Solution
This startup offers an automated microfluidic 3D cellular assay platform that enables high-throughput screening of drug candidates and personalized medicine approaches. The technology allows for the simultaneous testing of up to 800 conditions on 1,000 microtumors, significantly reducing the required patient sample size compared to traditional methods. By miniaturizing and automating the testing process, the platform accelerates drug discovery, enhances the predictability of preclinical studies, and facilitates personalized treatment strategies. The system integrates standard assays on a chip, such as CRISPR, T-cell, and cytotoxicity assays, to provide a comprehensive solution for drug development and validation.
Target Audience
The primary target audience includes pharmaceutical companies, biotech firms, and research institutions involved in drug discovery, preclinical studies, and personalized medicine.
Features
- Automated microfluidic platform for high-throughput 3D cell culture and drug screening
- Capability to test up to 800 conditions on 1,000 microtumors simultaneously
- Integration of standard assays on chip, including CRISPR, T-cell potency, and cytotoxicity assays
- Miniaturization of sample volume, requiring 1,000 times less patient sample than competitors
- Rapid turnaround time of approximately one week
- Automated operation, eliminating the need for specialized lab personnel